https://www.selleckchem.com/products/Rapamycin.html MUC1, a type I transmembrane glycoprotein, mediates tumor growth and cellular differentiation in various types of cancers. However, the mechanism of MUCI in ovarian cancer has not been fully clarified. In our study, we have observed that MUC1 can play a crucial role in the development and progression of ovarian cancer and act as a predictive marker. We also found that MUC1 could increase the expression of EGFR, and MUC1-EGFR co-administration could promote the cellular growth via the AKT pathway. Taxol is an important drug for treating ovarian cancer, which can prevent cancer recurrence and reduce mortality. Our data have collectively reflected that Taxol can prevent ovarian cancer with abnormal expression of MUC1. The present study was designed to explore the function of HOXB5 in breast cancer and related signaling pathway. Breast cancer tissues and non-cancerous tissues were collected from 82 cases who were pathologically diagnosed with breast cancer. The mRNA level of HOXB5 was detected via quantitative real-time polymerase chain reaction (qRT-PCR). Chi-square test was adopted to analyze the association of HOXB5 with clinical features. The viability, migration and invasion of breast cancer cells were detected through MTT and Transwell assays, respectively. Protein analysis was performed adopting western blot analysis. HOXB5 expression was increased in breast cancer tissues and cells, and showed positive correlation with tumor size (P = 0.028), TNM stage (P = 0.048), and lymph node metastasis (P = 0.002). Losing HOXB5 expression suppressed clone formation, proliferation, migration and invasion of breast cancer cells. The knockdown of HOXB5 significantly inactivated wnt/β-catenin pathway. Furthermore, wnt/β-catenin pathway had the potential to neutralize the oncogenic function of HOXB5 in breast cancer. HOXB5 may be involved in the invasive progression of breast cancer. The function of HOXB5 in breast cancer was m